• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    U

    Urologic Research Institute

    EST. 2006
    24论文总数
    239引用总数

    论文量&引用量时间轴

    机构学者

    论文(24)

    年份
    起
    –
    止
    排序
    1Erectile Dysfunction Severity As a Clinical Marker of High-Grade Prostate Cancer at Presentation
    M. Sayan, G. S. Miric, R. W. Galbreath, R. W. Fiano, K. Wallner, S. Moningi, A. C. Smart, J. E. Leeman, M. T. King, P. F. Orio

    Purpose/Objective(s) As active surveillance expands to selected favorable intermediate-risk patients, improved identification of high-grade disease at diagnosis is increasingly important. We hypothesized that baseline erectile dysfunction (ED) severity identifies patients more likely to harbor high-grade prostate cancer at presentation. Materials/Methods We analyzed 2,445 consecutive patients treated with low-dose-rate brachytherapy (2001–2018) who completed a pretreatment IIEF-6 questionnaire without pharmacologic or mechanical support. ED severity was classified as severe (1–10), moderate/mild (11–24), or normal (25–30). Associations between ED severity and PSA, percent positive biopsies, Gleason group, NCCN risk category, and comorbidities were evaluated using chi-square and multivariable logistic regression models adjusting for age. Results Severe ED was significantly associated with higher PSA (p=0.008), greater percent positive biopsies (p=0.002), and higher Gleason group distribution (p<0.001). Patients with severe ED more frequently harbored Gleason group 4–5 disease compared with those with normal erectile function. ED severity was also associated with increased prevalence of hypertension, diabetes, cardiovascular disease, and tobacco exposure (all p<0.001). Conclusion Baseline ED severity identifies patients more likely to harbor high-grade disease at diagnosis, independent of age. In the era of expanding active surveillance, ED severity may represent a readily available host-level biomarker that identifies patients who could benefit from intensified diagnostic evaluation and monitoring.

    2026INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS(2026)
    引用
    AI阅读
    加入学术空间
    2P0202: Comprehensive Transperineal Prostate Biopsy Positively Impacts Oncologic Outcomes in Low-Dose Rate Prostate Brachytherapy Patients
    Shalini Moningi,Grgur Mirić,Robert Galbreath,Ryan Fiano,Kent Wallner,Martin King,Peter Orio,Mutlay Sayan

    Purpose Conventional standard prostate biopsy techniques underestimate tumor grade and volume in up to 40% of cases. The integration of MRI into biopsy protocols has improved accuracy, but MRI still misses 15% of clinically significant cancers. Transperineal approaches with either a local anesthesia (laTP) or operating room (transperineal template guided mapping biopsy- TTMB) technique provides biopsy access to the entirety of the gland with sampling of all anatomic regions. In this study, we evaluate whether the extent of prostate biopsy impacts oncologic outcomes to include biochemical failure (BF), prostate cancer-specific mortality (PCSM), and overall mortality (OM). Materials and Methods This was a prospective, single institution cohort study of 3093 consecutive patients treated with low-dose rate brachytherapy (91.1% Pd-103) for clinically localized prostate cancer from April 1995-November 2018. Patients were stratified by the number of prostate biopsy cores and biopsy technique (1-17/TRUS, 18-30/laTP, >30/TTMB). Post-implant dosimetry was based on day 0 CT evaluation. BF was defined as a PSA> 0.40 after nadir. Patients with metastatic prostate cancer or non-metastatic castrate resistant disease who died of any cause were classified as dead of prostate cancer. All other deaths were attributable to the immediate cause of death. Multiple clinical, diagnostic, pathologic, and treatment parameters were analyzed for impact on survival outcomes. Results The median patient age was 65 years and the median pre-treatment PSA was 6.2ng/ml. The median f/u was 11.1 years (TRUS 12.1, laTP 5.3, TTMB 8.8 years, respectively, p<0.001). The TTMB cohort presented with lower pre-treatment PSA (p=0.003), lesser clinical stage (p<0.001), but were diagnosed with higher Gleason Group (GG) (p<0.001), were less likely to receive ADT (p<0.001) and more likely to receive EBRT (p<0.001). The median post-treatment PSA in biochemically controlled patients was <0.01 ng/ml. TTMB decreased BF for low, favorable and unfavorable risk groups but not high risk when compared to TRUS or laTP (p=0.009). TTMB reduced PCSM for GG 1-4 (p=0.01), but not GG5. In Fine-Gray analysis, BF was best predictedby TTMB (SHR 0.434:95% CI 0.200-0.940; p<0.001) and GG (SHR 3.397:95% CI 2.456-4.204; o<0.001). PCSM was most closely related to GG (SHR 6.232: 95% CI 3.065-12.669; p<0.001), while in Cox regression, OM was impacted by age (HR 1.095:95% CI 1.085-1.106; p<0.001) and number of comorbidities (HR 1.579: 95% CI 1.371-1.187; p<0.001). Conclusion Despite the ability of laTP to biopsy all regions of the prostate gland with substantially more biopsy cores, significant improvements in oncologic outcomes were not discerned when compared to TRUS. In contrast, 3-dimensional mapping (TTMB) diagnosed more high grade lesions, improved biochemical control and decreased PCSM for all patients except those with high risk disease or GG5 histology. Despite TTMB’s ability to more accurately determine tumor grade and volume, to optimize treatment planning and to improve oncologic outcomes, TTMB has not been universally accepted because of labor intensiveness and the integration of MRI into biopsy algorithms.

    2026Brachytherapy(2026)
    引用
    AI阅读
    加入学术空间
    3PPP03 Presentation Time: 9:48 AM: Erectile Dysfunction Severity As a Vascular Biomarker Predicting Cardiovascular Mortality in Patients with Prostate Cancer
    Peter Orio, Grgur Mirić, Robert Galbreath, Ryan Fiano, Kent Wallner, Shalini Moningi, Alicia Smart, Jon Leeman, Martin King, Mutlay Sayan

    Purpose Erectile dysfunction (ED) may represent early systemic vascular disease due to small-vessel atherosclerosis. We hypothesized that baseline ED severity independently predicts cardiovascular-specific mortality following definitive prostate radiation therapy and functions as a clinically accessible vascular biomarker. Materials and Methods We analyzed 2,445 consecutive patients treated with low-dose-rate brachytherapy (2001-2018) who completed a pretreatment IIEF-6 questionnaire without pharmacologic or mechanical support. ED severity was classified as severe (1-10), moderate/mild (11-24), or normal (25-30). The primary endpoint was cardiovascular-specific mortality. Secondary endpoints included overall mortality (OM), biochemical failure, and prostate cancer-specific mortality (PCSM). Cox regression evaluated OM, and competing risk regression (Fine and Gray) assessed cardiovascular death. Multivariable models adjusted for age, PSA, Gleason group, ADT, EBRT, hypertension, diabetes, tobacco use, cardiovascular disease, and comorbidity burden. Results At a median follow-up of 10 years, severe ED independently predicted worse OM (vs normal function HR 0.68, p<0.001). The association between ED severity and OM was significant in patients aged 60-69 and ≥70, but not in those ≤59 years. In competing risk analysis, ED severity was strongly associated with cardiovascular mortality (overall p<0.001). Compared with severe ED, normal erectile function was associated with a 65% relative reduction in cardiovascular death (HR 0.35, p<0.001), independent of established cardiovascular disease and risk factors. ED severity was not associated with biochemical failure (p=0.682) or PCSM (p=0.649). Conclusions Baseline ED severity independently predicts cardiovascular mortality—but not prostate cancer-specific death—after definitive radiation therapy. These findings support ED as a readily available vascular biomarker within oncology practice. Incorporating ED severity into routine assessment may identify patients at increased cardiovascular risk and create an opportunity for earlier preventive intervention.

    2026Brachytherapy(2026)
    引用
    AI阅读
    加入学术空间
    4Medical Management of Modifiable Risks: Improving Survival in High-Risk Prostate Cancer Patients Receiving Brachytherapy.
    Shalini Moningi,Grgur Mirić,Robert W Galbreath,Ryan Fiano,Kent E Wallner,Mutlay Sayan, Peter F Orio,Martin King

    Background: High-risk (HR) prostate cancer has a propensity for local and distant progression with ultimate death, mandating aggressive locoregional and systemic treatment approaches to maximize oncologic outcomes. Although brachytherapy (BT) with supplemental therapies has demonstrated favorable biochemical and quality of life outcomes, improvements in overall survival have been hampered by an excessive incidence of non- prostate cancer deaths. In this HR study, we report on biochemical failure (BF), prostate cancer-specific mortality (PCSM), overall mortality (OM) and patterns of death with recommendations for the mitigation of non-prostate cancer deaths. Materials and Methods: From April 1995 to November 2018, 577 consecutive HR patients were treated with LDR BT (97.9% Pd-103). Patients were stratified into three age cohorts: ≤ 59, 60-69 and ≥70 years. The BT prescription dose was prescribed to the prostate gland with generous peri-prostatic margins and the proximal 10mm of the seminal vesicles. 94.6% received supplemental EBRT (45-50.4 Gy) and 63.3% received androgen deprivation therapy (ADT) (median duration 12 months). Post-implant CT-based dosimetry was performed on day 0. BF was defined as a PSA > 0.40 ng/mL after nadir. The cause of death was determined for each patient. Patients with metastatic prostate cancer or non-metastatic castrate resistant prostate cancer who died of any cause were classified as dead of prostate cancer. All other deaths were attributed to the immediate cause. Multiple clinical, pathologic and treatment were evaluated for impact on patient outcomes. Results: Of the patients, 87.5% (median follow-up 8.9 years) presented with a single HR factor. The day 0 D90 was 122.5%. Overall, the 15-year BF, PCSM and OM were 12.4%, 5.6% and 51.7%. When stratified by age, there was no significant difference in BF or PCSM. The median post- treatment PSA in biochemically controlled patients was <0.01 ng/mL. In all three cohorts, OM increased linearly for the first 10 years and then approximately doubled from years 10 to 15. Moreover, 239 patients died: 10.9% due to prostate cancer, 38.1% from cardiovascular (CV) disease and 28.4% from other malignancies (to include one rectal and three bladder cancers). In MVA, BF was most closely related to percent positive biopsies (p < 0.001, SHR 1.018), PCSM to Gleason score (p = 0.004, SHR 2.884) and percent positive biopsies (p = 0.005, SHR 1.021) and OM to age (p < 0.001, HR 1.075) and tobacco (p < 0.001, HR 2.374). Conclusions: Despite high cancer control rates, overall survival was limited by a preponderance of CV and non-prostate cancer deaths, which were 6 times more likely than prostate cancer deaths. The implementation of a comprehensive multidisciplinary survivorship program will be essential to impact longevity in this patient population.

    2026Journal of clinical medicine(2026)
    引用
    AI阅读
    加入学术空间
    5Erectile Dysfunction Severity As a Vascular Biomarker Predicting Cardiovascular Mortality in Patients with Prostate Cancer
    M. Sayan, G. s. Miric, R. w. Galbreath, R. w. Fiano, K. Wallner, S. Moningi, A. c. Smart, J. e. Leeman, M. t. King, P. f. Orio

    Purpose/Objective(s) Erectile dysfunction (ED) may represent early systemic vascular disease due to small-vessel atherosclerosis. We hypothesized that baseline ED severity independently predicts cardiovascular-specific mortality following definitive prostate radiation therapy and functions as a clinically accessible vascular biomarker. Materials/Methods We analyzed 2,445 consecutive patients treated with low-dose-rate brachytherapy (2001–2018) who completed a pretreatment IIEF-6 questionnaire without pharmacologic or mechanical support. ED severity was classified as severe (1–10), moderate/mild (11–24), or normal (25–30). The primary endpoint was cardiovascular-specific mortality. Secondary endpoints included overall mortality (OM), biochemical failure, and prostate cancer–specific mortality (PCSM). Cox regression evaluated OM, and competing risk regression (Fine and Gray) assessed cardiovascular death. Multivariable models adjusted for age, PSA, Gleason group, ADT, EBRT, hypertension, diabetes, tobacco use, cardiovascular disease, and comorbidity burden. Results At a median follow-up of 10 years, severe ED independently predicted worse OM (vs normal function HR 0.68, p<0.001). The association between ED severity and OM was significant in patients aged 60–69 and ≥70, but not in those ≤59 years. In competing risk analysis, ED severity was strongly associated with cardiovascular mortality (overall p<0.001). Compared with severe ED, normal erectile function was associated with a 65% relative reduction in cardiovascular death (HR 0.35, p<0.001), independent of established cardiovascular disease and risk factors. ED severity was not associated with biochemical failure (p=0.682) or PCSM (p=0.649). Conclusion Baseline ED severity independently predicts cardiovascular mortality—but not prostate cancer–specific death—after definitive radiation therapy. These findings support ED as a readily available vascular biomarker within oncology practice. Incorporating ED severity into routine assessment may identify patients at increased cardiovascular risk and create an opportunity for earlier preventive intervention.

    2026INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 24 篇论文

    合作机构(40)

    华盛顿大学合作论文 12
    克利夫兰诊所合作论文 8
    Bethany College (Kansas)合作论文 8
    达纳 - 法伯癌症研究所合作论文 7
    丹娜—法伯癌症研究所合作论文 5
    多伦多大学合作论文 2
    延世大学合作论文 2
    新泽西州立大学癌症研究所合作论文 2
    哈佛医学院合作论文 2
    Peter MacCallum 癌症中心合作论文 1

    机构统计